JPMorgan downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $30, down from $45. The company has seen continued setbacks on the pipeline front, the analyst tells investors in a research note. The firm says that while Amphastar’s generic business remains better positioned than some peers, both glucagon and epinephrine are eroding faster than the Street was expecting. As such, it sees better opportunities elsewhere in the space.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Pharmaceuticals’ Mixed Earnings Call Insights
- Amphastar price target lowered to $35 from $40 at Wells Fargo
- Cautious Hold Rating for Amphastar Pharmaceuticals Amid Competitive Pressures and Revenue Challenges
- Amphastar Pharmaceuticals: Neutral Stance Amid Mixed Financial Outlook and Pipeline Uncertainty
- Amphastar Pharmaceuticals Reports Q1 2025 Earnings